BENITEC BIOPHARMA LIMITED Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
Name of entity
Rule 4.7B
BENITEC BIOPHARMA LIMITED
ABN
Quarter ended ("current quarter")
64 068 943 662
30 September 2018
Consolidated statement of cash flows
Current quarter
$A'000
Year to date (3 months)
$A'000
+ See chapter 19 for defined terms. 01/09/2016
1. | Cash flows from operating activities | ||
1.1 | Receipts from customers | 13,569* | 13,569 |
1.2 | Payments for | ||
(a) research and development | (2,822) | (2,822) | |
(b) product manufacturing and operating | - | - | |
costs | |||
(c) advertising and marketing | - | - | |
(d) leased assets | - | - | |
(e) staff costs | (991) | (991) | |
(f) administration and corporate costs | (1,672) | (1,672) | |
1.3 | Dividends received (see note 3) | - | - |
1.4 | Interest received | 44 | 44 |
1.5 | Interest and other costs of finance paid | - | - |
1.6 | Income taxes paid | - | - |
1.7 | Government grants and tax incentives | - | - |
1.8 | Other (refund of CRO prepayment) | - | - |
1.9 | Net cash from / (used in) operating | ||
activities | |||
8,128 | 8,128 | ||
Appendix 4C Page 1 |
*Payment received from Axovant Sciences GmbH on 9 July 2018.
+ See chapter 19 for defined terms. Appendix 4C Page 2
2. | |||
2.1 | |||
(a) property, plant and equipment | (36) | (36) | |
(b) businesses (see item 10) | - | - | |
(c) investments | - | - | |
(d) intellectual property | - | - | |
(e) other non-current assets | - | - | |
2.2 | Proceeds from disposal of: | ||
(a) property, plant and equipment | - | - | |
(b) businesses (see item 10) | - | - | |
(c) investments | - | - | |
(d) intellectual property | - | - | |
(e) other non-current assets | - | - | |
2.3 | Cash flows from loans to other entities | - | - |
2.4 | Dividends received (see note 3) | - | - |
2.5 | Other (deposits) | - | - |
2.6 | Net cash from / (used in) investing | ||
activities | |||
(36) | (36) | ||
3. | Cash flows from financing activities | ||
3.1 | Proceeds from issues of shares | - | - |
3.2 | Proceeds from issue of convertible notes | - | - |
3.3 | Proceeds from exercise of share options | - | - |
3.4 | Transaction costs related to issues of | (20) | (20) |
shares, convertible notes or options | |||
3.5 | Proceeds from borrowings | - | - |
3.6 | Repayment of borrowings | - | - |
3.7 | Transaction costs related to loans and | - | - |
borrowings | |||
3.8 | Dividends paid | - | - |
3.9 | Other (capital raising cost) | - | - |
3.10 | Net cash from / (used in) financing | ||
activities | |||
(20) | (20) | ||
01/09/2016 |
Cash flows from investing activities Payments to acquire:
4. Net increase / (decrease) in cash and cash equivalents for the period
4.1 Cash and cash equivalents at beginning ofquarter/year to date
16,085 16,085
4.2 Net cash from / (used in) operating activities (item 1.9 above)
8,128 8,128
4.3 Net cash from / (used in) investing activities (item 2.6 above)
(36) (36)
4.4 Net cash from / (used in) financing activities (item 3.10 above)
(20) (20)
4.5 Effect of movement in exchange rates on cash held
440 440
4.6 Cash and cash equivalents at end of quarter
24,597 24,597
5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts
Current quarterPrevious quarter
$A'000
$A'000
5.1 Bank balances
18,597 9,575
5.2 Call deposits
6,000 6,510
5.3 Bank overdrafts
5.4 Other (provide details)
- -- -
5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)
24,597
16,085
+ See chapter 19 for defined terms. 01/09/2016
6. Payments to directors of the entity and their associates
Current quarter
$A'000
6.1 Aggregate amount of payments to these parties included in item 1.2
6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
38 nil
6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2
Payments related to directors' fees ($37k) and payments to related party ($1k)
7. Payments to related entities of the entity and their associatesCurrent quarter
$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- -
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2
8. Financing facilities available
Add notes as necessary for an understanding of the position
8.1 Loan facilities
8.2 Credit standby arrangements
8.3 Other (please specify)
Total facility amount
Amount drawn at
at quarter end
quarter end
$A'000
$A'000
- - -
- - -
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.
+ See chapter 19 for defined terms.
01/09/2016
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
9. | Estimated cash outflows for next quarter | |
9.1 | Research and development * | * 1,902 |
9.2 | Product manufacturing and operating costs | - |
9.3 | Advertising and marketing | - |
9.4 | Leased assets | - |
9.5 | Staff costs | 1,000 |
9.6 | Administration and corporate costs | 941 |
9.7 | Other (provide details if material) | 156 |
9.8 | Total estimated cash outflows | 3,999 |
$A'000
* Research and Development costs comprise several payments including large one off payments. The timing of these payments has inherent uncertainty and actual payment timings may differ from the forecast period. Changes in the expected timing of these payments may materially affect forecast quarterly cashflows.
10. Acquisitions and disposals of business entitiesAcquisitions
Disposals
(items 2.1(b) and 2.2(b) above)
10.1 Name of entity
N/A
10.2 Place of incorporation or registration
N/A
N/A N/A
10.3 Consideration for acquisition or disposal
N/A
N/A
10.4 Total net assets
10.5 Nature of business
N/A N/A
N/A N/A
Compliance statement
1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
2 This statement gives a true and fair view of the matters disclosed.
Sign here:
............................................................
Date:
29 October 2018
(Director/Company Secretary)Print name:
....... Megan Boston ..........................
+ See chapter 19 for defined terms. 01/09/2016
Attachments
- Original document
- Permalink
Disclaimer
Benitec Biopharma Ltd. published this content on 29 October 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 28 October 2018 22:46:07 UTC
